ANTIBODIES REACTIVE WITH AN EPITOPE LOCATED IN THE N-TERMINAL REGION OF MUC5AC COMPRISING CYSTEINE-RICH SUBDOMAIN 2 (CYS2)

摘要

The present invention concerns compositions and methods of use of antibodies or antibody fragments that bind to an epitope located within the second cysteine-rich domain (Cys2, amino acid residues 1575-1725) of MUC5AC. The antibodies bind with high specificity and selectivity to pancreatic cancer and are of use for therapy, detection and/or diagnosis of pancreatic cancer. In preferred embodiments, therapeutic antibody may be conjugated to at least one therapeutic agent, such as 90Y. Both in vivo and in vitro detection of pancreatic cancer may be performed with the subject methods and compositions. Specific dosages of radiolabeled antibody and/or gemcitabine, of use in human pancreatic cancer patients, are disclosed herein.

主权项

1. A method of treating a cancer that expresses MUC5ac comprising administering to a human subject with a cancer that expresses MUC5ac a humanized anti-MUC5ac monoclonal antibody or antigen-binding fragment thereof that binds to an epitope located within the second cysteine-rich domain (Cys2, amino acid residues 1575-1725) of MUC5ac, wherein the anti-MUC5ac antibody is conjugated to at least one therapeutic agent.